SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-277083
Filing Date
2023-11-14
Accepted
2023-11-14 16:01:54
Documents
13
Period of Report
2023-11-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d367592d8k.htm   iXBRL 8-K 30775
2 EX-10.1 d367592dex101.htm EX-10.1 42885
  Complete submission text file 0001193125-23-277083.txt   213502

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA impl-20231107.xsd EX-101.SCH 2840
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE impl-20231107_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE impl-20231107_pre.xml EX-101.PRE 11701
7 EXTRACTED XBRL INSTANCE DOCUMENT d367592d8k_htm.xml XML 3523
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 231405679
SIC: 2834 Pharmaceutical Preparations